论文部分内容阅读
目的 了解本地区痤疮患者痤疮丙酸杆菌对克林霉素(CLI,Clindamycin)和甲硝唑(MNZ,Metronidazole)的耐药情况.方法 体外分离、培养痤疮丙酸杆菌,采用基质辅助激光解吸附电离飞行时间质谱(MALDI-TOF MS)技术进行鉴定,并按照琼脂稀释法进行药敏实验.结果 212例痤疮患者中分离出156株痤疮丙酸杆菌,对CLI和MNZ的耐药率分别为:28.21％ (44/156)和100％(156/156),CLI和MNZ能抑制90％受试菌所需的最低抑菌浓度(MIC90)为:MIC90CLI≥256,MIC90MNZ≥256.结论 本地区痤疮患者痤疮丙酸杆菌对MNZ 100％耐药、CLI 28.21％耐药,且均为高度耐药.“,”Objective To acquaint the regional drug resistant situation of clindamycin (CLI) and metronidazole (MNZ) in acne vulgaris patients.Methods First in vitro to isolate and culture the Propionibacterium acnes,and then to evaluate them with the method of matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS),last agar dilution method was used to conduct the drug resistance test.Results Among the 212 acne cases,156 strains of P.acnes were isolated.The resistance rates of clindamycin and metronidazole were:28.21％ (44/156) and 100％ (156/156) respectively.The minimum inhibitory concentration (MIC) required for clindamycin and metronidazole to inhibit 90％ of the tested bacteria in this batch was:MICg0MNZ ≥256 and MIC90cLI ≥256 respectively.Conclusion Acne patients in this region were 100％ resistant to metronidazole and 28.21％ resistant to clindamycin.Both antibiotics showed high degree of drug resistance.